The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of ...

The FDA has approved a supplemental biologics application for Leqembi Iqlik subcutaneous injection for maintenance dosing in ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...

While administering monoclonal antibodies via intravenous infusion is standard practice to prevent severe hospitalization and death in outpatients with COVID-19, new research from UPMC shows giving ...

While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction ...

Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...